We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
    • White Papers
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » NIH to Begin Evaluating Moderna Vaccine Modified Against South African Strain

NIH to Begin Evaluating Moderna Vaccine Modified Against South African Strain

February 25, 2021

The NIH’s National Institute of Allergy and Infectious Diseases (NIAID) will soon begin a phase 1 clinical trial of Moderna’s variant-specific COVID-19 vaccine candidate, mRNA-1273.351, which has been tailored to better protect against the virus’ South African mutation. Moderna will also conduct trials of its own.

The drugmaker announced Wednesday that it has shipped doses of its modified COVID-19 vaccine to the NIH for evaluation in a phase 1 trial of the candidate. The NIAID, which is both leading and funding the research, will assess if the rejiggered vaccine can serve as a viable booster shot against the fast-spreading strain. The trial will kick off once the FDA has given its go-ahead.

Moderna, which first announced its efforts on a modified vaccine a month ago, said it is also spearheading its own clinical studies to support regulatory filings for any booster shot or updates to its primary vaccine. It plans to evaluate the modified vaccine on its own, the modified vaccine combined with the company’s original vaccine and a third shot of its original vaccine as a booster. It will also evaluate the original and modified vaccine combination as a primary vaccination for patients who are seronegative — meaning they don’t have antibodies against the virus in their blood serum.

The two-dose Moderna vaccine looks to have diminished efficacy against the South African mutation but appears to still offer protection. The company said that “while initial data confirm that [our] vaccine provides neutralizing activity against variants of concern,” it is taking action against viral mutations “out of an abundance of caution.”

“We are moving quickly to test updates to the vaccines that address emerging variants of the virus in the clinic. Moderna is committed to making as many updates to our vaccine as necessary until the pandemic is under control,” said Moderna CEO Stéphane Bancel. “We hope to demonstrate that booster doses, if necessary, can be done at lower dose levels, which will allow us to provide many more doses to the global community in late 2021 and 2022 if necessary.”

The company intends to follow the FDA’s recently published guidance on amending Emergency Use Authorizations for modified vaccines by evaluating immunogenicity and safety in both nonvaccinated patients and patients who have received its vaccine. Peter Marks, director of the Center for Biologics Evaluation and Research, has said the agency expects modified vaccine trials to take around “two to three months” and consist of “a few hundred individuals” (DID, Feb. 23). — James Miessler

COVID-19

    Upcoming Events

    • 28Sep

      The Cost of Counterfeiting: Why You Need a Plan to Secure Your Medical Device Supply Chain

    • 28Sep

      Calculating Sample Size to Satisfy FDA Expectations

    • 11Oct

      GMP Quality Management vSummit 2023: Where Quality Meets Risk

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    • 02Nov

      How UDI and UDI Data Can — and Must — Be Used for More Than Just Device Identification

    Featured Products

    • FDA, FTC and DOJ Enforcement of Medical Device Regulations

      FDA, FTC and DOJ Enforcement of Medical Device Regulations

    • Using Real-World Evidence in Drug and Device Submissions

      Using Real-World Evidence in Drug and Device Submissions

    Featured Stories

    • Expert Says FDA Under No Obligation to Educate Companies on Inspection Rights

    • FDA Deems Hamilton Ventilator Recall Class I for Software Issue Causing Device to Stop

    • Survey Shows Nearly All Pharm Techs Face Drug Shortages, Pfizer Plant Shortages Continue Until 2024

    • FDA Shares Premarket Requirements for Device Cybersecurity in Final Guidance

    The Revised ICH E8: A Guide to New Clinical Trial Requirements

    Learn More
    • Drug Products
      • Quality
      • Regulatory Affairs
      • GMPs
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Device Products
      • Quality
      • Regulatory Affairs
      • QSR
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Clinical Products
      • Trial Design
      • Data Integrity
      • GCP
      • Inspections and Audits
      • Transparency
    • Privacy Policy
    • Do Not Sell or Share My Data
    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing